Cargando…
Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review
Use of α-androgenic receptor blockers remains a mainstay therapeutic approach for the treatment of urological diseases. Silodosin is recommended over other α-blockers for the treatment of lower urinary tract symptoms (LUTS) and benign prostate hyperplasia (BPH), due to its high α(1A) uroselectivity....
Autores principales: | Jindan, Luo, Xiao, Wang, Liping, Xie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427207/ https://www.ncbi.nlm.nih.gov/pubmed/36051157 http://dx.doi.org/10.2147/DDDT.S373659 |
Ejemplares similares
-
Silodosin in the treatment of benign prostatic hyperplasia
por: Rossi, Maxime, et al.
Publicado: (2010) -
Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia
por: Sakata, Koichi, et al.
Publicado: (2012) -
Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
por: Yoshida, Masaki, et al.
Publicado: (2011) -
Management of benign prostatic hyperplasia with silodosin
por: Yamanishi, Tomonori, et al.
Publicado: (2009) -
Focus on Silodosin: Pros and Cons of Uroselectivity
por: Califano, Gianluigi, et al.
Publicado: (2020)